[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA023067B1 - Соединение, представляющее собой антагонист лейкотриена b - Google Patents

Соединение, представляющее собой антагонист лейкотриена b Download PDF

Info

Publication number
EA023067B1
EA023067B1 EA201491099A EA201491099A EA023067B1 EA 023067 B1 EA023067 B1 EA 023067B1 EA 201491099 A EA201491099 A EA 201491099A EA 201491099 A EA201491099 A EA 201491099A EA 023067 B1 EA023067 B1 EA 023067B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
cells
pharmaceutically acceptable
aaa
ethyl
Prior art date
Application number
EA201491099A
Other languages
English (en)
Russian (ru)
Other versions
EA201491099A1 (ru
Inventor
Дуглас Ричард Стак
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201491099A1 publication Critical patent/EA201491099A1/ru
Publication of EA023067B1 publication Critical patent/EA023067B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201491099A 2012-01-10 2013-01-04 Соединение, представляющее собой антагонист лейкотриена b EA023067B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261584975P 2012-01-10 2012-01-10
US201261585799P 2012-01-12 2012-01-12
PCT/US2013/020195 WO2013106238A1 (fr) 2012-01-10 2013-01-04 Composé antagoniste des leucotriènes b4

Publications (2)

Publication Number Publication Date
EA201491099A1 EA201491099A1 (ru) 2014-11-28
EA023067B1 true EA023067B1 (ru) 2016-04-29

Family

ID=47604162

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491099A EA023067B1 (ru) 2012-01-10 2013-01-04 Соединение, представляющее собой антагонист лейкотриена b

Country Status (14)

Country Link
US (1) US9187411B2 (fr)
EP (1) EP2802557B1 (fr)
JP (1) JP2015509917A (fr)
KR (1) KR20140099546A (fr)
CN (1) CN104011012B (fr)
AU (1) AU2013208260A1 (fr)
BR (1) BR112014016450A2 (fr)
CA (1) CA2857521C (fr)
EA (1) EA023067B1 (fr)
ES (1) ES2571452T3 (fr)
IN (1) IN2014MN01014A (fr)
MX (1) MX2014008452A (fr)
WO (1) WO2013106238A1 (fr)
ZA (1) ZA201404732B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017095725A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Sulfonamides d'aryle utilisés en tant qu'antagonistes de blt1
WO2017095723A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
WO2017095722A1 (fr) 2015-11-30 2017-06-08 Merck Sharp & Dohme Corp. Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
US20190382363A1 (en) 2015-11-30 2019-12-19 Merck Sharp & Dohme Corp. Aryl sulfonamides as blt1 antagonists

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5105017A (en) * 1983-07-18 1992-04-14 Eli Lilly And Company Leukotriene antagonist intermediates
GB9027023D0 (en) 1990-12-12 1991-01-30 Wellcome Found Anti-atherosclerotic aryl compounds
CN1035001C (zh) * 1993-01-02 1997-05-28 伊莱利利公司 取代的苯基苯酚基白三烯拮抗物
WO1996036347A1 (fr) 1995-05-17 1996-11-21 Eli Lilly And Company Utilisation d'antagonistes de la leucotriene pour le traitement de la maladie d'alzheimer
WO1998042346A1 (fr) 1997-03-21 1998-10-01 Eli Lilly And Company Antagonistes de leucotriene utiles dans le traitement de lesions ischemiques de reperfusion
WO2001034135A2 (fr) 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
WO2001034198A2 (fr) 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
CN1237968C (zh) 2000-05-09 2006-01-25 克赖顿大学 抑制癌细胞的增殖和诱导其凋亡的方法
AU2001275115A1 (en) * 2000-06-02 2001-12-17 Eli Lilly And Company Methods for coupling benzoyl compounds and amino substituted bicyclic derivatives and enantiomerically pure or enriched compositions made therefrom
WO2004073606A2 (fr) 2003-02-14 2004-09-02 Eli Lilly And Company Derives de sulfonamides utilises comme modulateurs du recepteur ppar

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462954A (en) * 1991-11-25 1995-10-31 Eli Lilly And Company Substituted phenyl phenol leukotriene antagonists

Also Published As

Publication number Publication date
CA2857521C (fr) 2016-03-01
EP2802557B1 (fr) 2016-04-06
US20140343151A1 (en) 2014-11-20
MX2014008452A (es) 2014-08-27
US9187411B2 (en) 2015-11-17
WO2013106238A1 (fr) 2013-07-18
CA2857521A1 (fr) 2013-07-18
ES2571452T3 (es) 2016-05-25
CN104011012A (zh) 2014-08-27
EA201491099A1 (ru) 2014-11-28
KR20140099546A (ko) 2014-08-12
JP2015509917A (ja) 2015-04-02
ZA201404732B (en) 2015-11-25
BR112014016450A2 (pt) 2019-09-24
EP2802557A1 (fr) 2014-11-19
IN2014MN01014A (fr) 2015-07-03
AU2013208260A1 (en) 2014-06-05
CN104011012B (zh) 2016-01-20

Similar Documents

Publication Publication Date Title
Kikuta et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function
Kroner et al. Mast cells are critical regulators of bone fracture–induced inflammation and osteoclast formation and activity
van der Horst et al. Targeting of αv-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer
Blaser et al. Deficiency of natriuretic peptide receptor 2 promotes bicuspid aortic valves, aortic valve disease, left ventricular dysfunction, and ascending aortic dilatations in mice
Amend et al. Thrombospondin‐1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts
JP6903585B2 (ja) 補体関連疾患の治療のための組成物および治療方法
US9084745B2 (en) Modulation of the Vps10p-domain for the treatment of cardiovascular disease
Valverde et al. Overexpression of bone sialoprotein leads to an uncoupling of bone formation and bone resorption in mice
US20170318057A1 (en) Modulation of the VPS10P-Domain Receptors for the Treatment of Cardiovascular Disease
EA023067B1 (ru) Соединение, представляющее собой антагонист лейкотриена b
Crockett et al. The matricellular protein CYR61 inhibits osteoclastogenesis by a mechanism independent of αvβ3 and αvβ5
Weng et al. Nogo-C regulates post myocardial infarction fibrosis through the interaction with ER Ca2+ leakage channel Sec61α in mouse hearts
Xiao et al. Deficiency of PDK1 in osteoclasts delays fracture healing and repair
Del Fattore et al. Bone and bone marrow: the same organ
Lewis et al. Therapeutic avenues in bone repair: Harnessing an anabolic osteopeptide, PEPITEM, to boost bone growth and prevent bone loss
US11260103B2 (en) Compositions and methods for delivering lypophilic agents to dental pulp and for enhancing dentin production
Lisewski et al. Increased aldosterone‐dependent Kv1. 5 recycling predisposes to pacing‐induced atrial fibrillation in Kcne3‐/‐mice
Yue et al. Discovery and evaluation of phenacrylanilide derivatives as novel potential anti-liver fibrosis agents
Zondervan et al. Thrombospondin‐2 spatiotemporal expression in skeletal fractures
Buchler et al. Quinazoline-2-Carboxamides as Selective PET Radiotracers for Matrix Metalloproteinase-13 Imaging in Atherosclerosis
Sinclair Emerging topics in atherosclerosis: HDL raising therapies
en Farmacie JOLIEN GEERS
CN104105498A (zh) 一种氧化ldl抑制剂
Lisewski et al. Increased aldosterone-dependent Kv1. 5 recycling predisposes to pacing-induced atrial fibrillation in
Owen Effect of coronary perivascular adipose tissue on vascular smooth muscle function in metabolic syndrome

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU